PRMT5 and hepatocellular carcinoma: In the METTL1 / WDR4 associated lncRNA risk signature, MYLK-AS1 promotes HCC progression by regulating the miR-424-5p/E2F7 axis and VEGFR-2 signaling pathway [40]; LINC01138 can interact with PRMT5 and promote metastasis and proliferation of HCC by enhancing its protein stability [41].